Latest Bone fracture Stories

TORONTO, June 15, 2012 /CNW/ - Join Osteoporosis Canada (OC) on June 17, 2012 as it celebrates 30 years of dedicated service to those with or at risk of osteoporosis.  Established in 1982, the first organization in the world committed solely to bone health. Osteoporosis Canada remains the only organization in Canada with this primary focus. Through its 22 chapters and network of health care professionals, OC disseminates information on building and maintaining bone health...

A study published online in May 2012, by the Archives of Internal Medicine, a publication of the American Medical Association, revealed that atypical femoral fractures were associated with bisphosphonate (including Fosamax) use. Fosamax, manufactured by Merck, belongs to the class of drugs known as bisphosphonates. It was approved by the FDA in 1995 and developed to treat post-menopausal osteoporosis and Paget's disease of bone. On March 3rd, 2010, the U.S FDA issued a drug safety...

The US Drug Watchdog says, "The osteoporosis drug called Fosamax, and out of the blue femur breaks is one of the most complicated issues we have ever encountered. For one, we are hearing from women, who were using Fosamax for five years or more, their femur broke, and typically they had to have at least one surgery to repair the femur. Often, if not in most cases these surgeries involve using a metal rod to reinforce the femur. Our greatest fear is most women, who have had this happen...

Bernstein Liebhard LLP reports that the latest Fosamax ONJ state court trial has been put on hold and instead the Court plans on trying the first group of Fosamax femur fracture lawsuits against Merck. New York, NY (PRWEB) June 08, 2012 Bernstein Liebhard LLP, a nationwide law firm representing clients who have filed Fosamax femur fracture lawsuits, reports that this group of lawsuits against Merck, the manufacturer of the widely prescribed osteoporotic drug, is moving towards trial. On...

ROSEMONT, Ill., June 7, 2012 /PRNewswire-USNewswire/ -- Below are highlights of new review articles appearing in the June 2012 issue of the JAAOS, as well as the full table of contents. Each news highlight, and listed title in the table of contents, includes a link to the abstract. Effects of Smoking on Bone and Joint HealthDuring cigarette use, hazardous gases and chemicals that can cause genetic mutations and the development of cancer are released into the bloodstream. One of these...

DALLAS, June 4, 2012 /PRNewswire/ -- ReportsnReports.com adds following new Medical Devices market research reports on the European and U.S. regions for 2012: A. European Markets for Gastrointestinal Endoscopic Devices The GI endoscopic market includes: - GI endoscopes - capsule endoscopy - virtual colonoscopy - stenting and dilation devices - ERCP devices - biopsy forceps - polypectomy snares...

Ennis & Ennis, PA Summarizes the Latest Fosamax Study that Confirms Long-Term Use of Biphosphonates, such as Fosamax and Boniva, Causes Atypical Femur Fractures (PRWEB) May 26, 2012 After the New England Journal of Medicine published their findings that use of biphosphonates is not deemed beneficial outside of a 3 to 5 year window, the Archives of Internal Medicine have confirmed that prolonged use of the drug increases risk for atypical fractures of the femur. Commonly used brand...

Bernstein Liebhard LLP reports on a new study that found an increased risk of atypical femur fractures in people who take Fosamax. New York, New York (PRWEB) May 22, 2012 Bernstein Liebhard LLP, a nationwide law firm representing clients who experienced Fosamax thigh fractures and other side effects, reports on a May 21, 2012 study by the Archives of Internal Medicine, which found that taking Fosamax increases the risk of an atypical femur fracture.* The study was conducted by doctors...

In April 2012, MHRA published an article revealing that there is recent epidemiological evidence of an increased risk of fracture with long-term use of PPIs (Proton Pump Inhibitors), including Nexium. Nexium, manufactured by AstraZeneca, is a medication that people take to prevent on-going heartburn. According to court documents, on April 19th, 2011, an Ohio woman, Ginny Begin, filed a lawsuit Texas Southern District Court (case no. 4:2011cv01489) against AstraZeneca, alleging that she...

(Ivanhoe Newswire) -- New research shows when it comes to bone-cancer-related fractures, pain can be reduced by drug treatment, but no one drug is superior. Researchers undertook a systematic review of the current evidence on bisphosphonate drugs, which are used to prevent bone damage in multiple myeloma. Severe back pain is a common symptom of multiple myeloma—a type of cancer that can cause fractures in long bones and the spine. Bisphosphonate drugs may help to reduce the occurrence of...